Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| OCGN | PRESS-RELEASE | mixed | 6/10 | Ocugen reported Q1 2026 EPS of -$0.06, a 16.1% miss vs consensus of -$0.05, with revenue of $1.53M (in line). The miss w | May 5, 2026 |
| IRON | PRESS-RELEASE | neutral | 5/10 | Disc Medicine reported Q1 2026 EPS of -$1.65, slightly beating the -$1.73 consensus by 4.6%, but net loss widened to $63 | May 5, 2026 |
| IRON | 8-K | neutral | 4/10 | Disc Medicine reported Q1 2026 results with a net loss of $63.5M ($1.65/share), wider than the $34.1M loss in Q1 2025, d | May 5, 2026 |
| OCGN | PRESS-RELEASE | bearish | 7/10 | Ocugen priced $115M of 6.75% convertible senior notes due 2034 at a 90% discount to par, with net proceeds of ~$99.5M ($ | May 5, 2026 |
| NERV | 8-K | neutral | 4/10 | Minerva Neurosciances reported Q1 2026 results with a GAAP net loss of $125.4M ($2.86/share) vs $3.8M ($0.50/share) a ye | May 5, 2026 |
| COGT | 8-K | neutral | 4/10 | Cogent Biosciences reported Q1 2026 net loss of $97.4M, wider than the $72.0M loss in Q1 2025, driven by increased R&D a | May 5, 2026 |
| SYRE | 8-K | mixed | 6/10 | Spyre Therapeutics reported Q1 2026 financial results with a net loss of $69.0M ($0.74 per share), wider than the $44.8M | May 5, 2026 |
| RYTM | 8-K | mixed | 6/10 | Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M (up 59% YoY from $37.7M) and GAAP EPS of -$0.83, beating conse | May 5, 2026 |
| CLYM | 8-K | neutral | 4/10 | Climb Bio hosted an R&D Spotlight event on May 5, 2026, presenting positive topline data for its subcutaneous budoprutug | May 5, 2026 |
| NVCT | 8-K | neutral | 4/10 | Nuvectis Pharma reported Q1 2026 financial results, highlighting continued enrollment in the NXP900 Phase 1b program and | May 5, 2026 |
| CYTK | PRESS-RELEASE | bullish | 8/10 | Cytokinetics announced positive topline results from the ACACIA-HCM Phase 3 trial of aficamten in non-obstructive HCM, m | May 5, 2026 |
| BBIO | PRESS-RELEASE | neutral | 3/10 | BridgeBio Pharma announced it will present additional Phase 3 data for encaleret in ADH1 at the 2026 European Congress o | May 5, 2026 |
| WLK | 8-K | bearish | 7/10 | Westlake reported a Q1 2026 GAAP net loss of $169M (-$1.31/share) on net sales of $2.65B, compared to a net loss of $40M | May 5, 2026 |
| WLKP | 8-K | bullish | 6/10 | Westlake Chemical Partners LP reported Q1 2026 net income attributable to the Partnership of $14.2M ($0.40/unit), a shar | May 5, 2026 |
| CMPX | 8-K | bullish | 7/10 | Compass Therapeutics reported Q1 2026 net loss of $18.3M ($0.10/share), slightly better than the $0.10 consensus estimat | May 5, 2026 |
| DTIL | 8-K | neutral | 4/10 | Precision BioSciences reported Q1 2026 revenue of $10.8M (up from ~$0.1M YoY) and a net loss of $(0.75)/share, narrowing | May 5, 2026 |
| FBLG | DEFA14A | neutral | 3/10 | FibroBiologics filed a DEFA14A (definitive additional proxy soliciting materials) on May 5, 2026, but the actual documen | May 5, 2026 |
| CLRB | PRESS-RELEASE | bullish | 8/10 | Cellectar Biosciences announced updated 12-month follow-up data from its Phase 2b CLOVER WaM trial of iopofosine I 131 i | May 5, 2026 |
| RYTM | PRESS-RELEASE | bullish | 7/10 | Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M, beating the $56.1M consensus, and an EPS loss of -$0.73, beat | May 5, 2026 |
| OCUL | PRESS-RELEASE | mixed | 6/10 | Ocular Therapeutix reported Q1 2026 EPS of -$0.29, beating consensus of -$0.32 by 9.4%, while revenue of $10.8M was belo | May 5, 2026 |
| MCRB | PRESS-RELEASE | bearish | 6/10 | Seres Therapeutics reported a Q1 2026 net loss of $19.9 million versus net income of $32.7 million in Q1 2025, which inc | May 5, 2026 |
| EDIT | PRESS-RELEASE | bearish | 6/10 | Editas Medicine reported Q1 2026 EPS of -$0.26, slightly worse than the -$0.24 consensus (a miss), while revenue of $2.8 | May 5, 2026 |
| ARVN | PRESS-RELEASE | neutral | 1/10 | Arvinas Inc. announced it will report its Q1 2026 results on May 12, 2026. | May 5, 2026 |
| RGEN | PRESS-RELEASE | bullish | 7/10 | Repligen reported Q1 2026 adjusted EPS of $0.48, beating the $0.38 consensus by 26.3%, and revenue of $194M (+15% YoY, + | May 5, 2026 |
| QURE | PRESS-RELEASE | bearish | 6/10 | uniQure reported Q1 2026 EPS of -$0.85, missing the consensus estimate of -$0.75 by 13.3%, and revenue of $3.6M, below t | May 5, 2026 |
| QURE | 8-K | neutral | 5/10 | Key pipeline updates include a scheduled Type B meeting with the FDA for AMT-130 in Huntington's disease and an expected | May 5, 2026 |
| OCUL | 8-K | neutral | 5/10 | Ocular Therapeutix reported Q1 2026 net revenue of $10.8M (up 0.8% YoY), essentially flat, and a net loss of -$0.40/shar | May 5, 2026 |
| RGEN | 8-K | bullish | 7/10 | Repligen reported Q1 2026 revenue of $194M (+15% YoY, +11% organic) and adjusted EPS of $0.48, beating the $0.38 consens | May 5, 2026 |
| ALKS | 8-K | mixed | 5/10 | Alkermes reported Q1 2026 revenue of $392.9M, up 28% YoY, driven by the Avadel acquisition adding LUMRYZ ($39.5M) and st | May 5, 2026 |
| VRDN | 8-K | neutral | 5/10 | Viridian Therapeutics reported Q1 2026 financial results, highlighting a net loss of $104.9M vs $86.9M a year ago, with | May 5, 2026 |